A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People using Anticoagulation StrategieS)

Trial Profile

A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People using Anticoagulation StrategieS)

Suspended
Phase of Trial: Phase III

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Rivaroxaban (Primary) ; Aspirin; Pantoprazole; Proton pump inhibitors
  • Indications Cardiovascular disorders; Coronary artery disease; Embolism and thrombosis; Heart failure; Myocardial infarction; NSAID-induced gastrointestinal damage; Peripheral arterial disorders; Stroke
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms COMPASS
  • Sponsors Bayer
  • Most Recent Events

    • 27 Aug 2017 Primary endpoint (Time from randomization to the first occurrence of either myocardial infarction, stroke, or cardiovascular death, rivaroxaban vs aspirin) has not been met as per results published in the New England Journal of Medicine
    • 27 Aug 2017 Results published in the New England Journal of Medicine
    • 27 Aug 2017 Results published in a Bayer media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top